Phase 2 rize study sub-analyses to be presented at the 2024 pediatric endocrine society annual meeting

Redwood city, calif., april 23, 2024 (globe newswire) -- rezolute, inc. (nasdaq: rzlt) (“rezolute” or the “company”), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced that a poster titled “an analysis of overnight hypoglycemia in patients with congenital hyperinsulinism: results from the rz358-606 (rize) study” will be presented at the pediatric endocrine society (pes) annual meeting, to be held may 2-5, 2024 at the sheraton grand chicago riverwalk.
RZLT Ratings Summary
RZLT Quant Ranking